MeSH term
Frequency | Condition_Probility | Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Humans | 1294 | 0.0 |
Renin-Angiotensin System/*drug effects | 2 | 1.0 |
Aged | 273 | 0.0 |
Risk | 2 | 0.0 |
Time Factors | 87 | 0.0 |
United States | 4 | 0.0 |
Aged, 80 and over | 87 | 0.0 |
Fatal Outcome | 3 | 0.0 |
Female | 631 | 0.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Mutation | 13 | 0.0 |
Research Support, Non-U.S. Gov't | 641 | 0.0 |
Animals | 342 | 0.0 |
CHO Cells | 9 | 0.0 |
Cricetulus | 2 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Genetic Vectors | 13 | 0.0 |
Half-Life | 10 | 1.0 |
Hamsters | 18 | 0.0 |
Hela Cells | 9 | 0.0 |
Proteins/metabolism | 3 | 0.0 |
RNA, Messenger/metabolism | 18 | 0.0 |
*Transcription, Genetic | 5 | 0.0 |
Transfection | 35 | 0.0 |
Antigens, CD/analysis | 4 | 0.0 |
Antigens, CD34/analysis | 7 | 1.0 |
*Apoptosis | 7 | 0.0 |
Cells, Cultured | 121 | 0.0 |
Fetal Blood/*cytology | 10 | 5.0 |
Immunophenotyping | 4 | 0.0 |
Karyotyping | 7 | 0.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
CpG Islands | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 3 | 1.0 |
Promoter Regions (Genetics) | 20 | 0.0 |
Tumor Cells, Cultured | 87 | 0.0 |
Anemia/etiology/*prevention & control | 4 | 100.0 |
Bone Marrow Transplantation | 7 | 2.0 |
Chronic Disease | 36 | 2.0 |
Dose-Response Relationship, Drug | 66 | 1.0 |
Erythropoietin/*therapeutic use | 68 | 78.0 |
Hematopoietic Stem Cell Transplantation | 7 | 3.0 |
Hypertension/etiology | 2 | 4.0 |
Neoplasms/*complications | 6 | 17.0 |
Quality of Life | 13 | 7.0 |
Survival Analysis | 8 | 0.0 |
Combined Modality Therapy | 13 | 1.0 |
English Abstract | 122 | 1.0 |
Erythropoietin, Recombinant/*therapeutic use | 30 | 81.0 |
Infant, Newborn | 50 | 1.0 |
Infant, Premature | 5 | 4.0 |
Retrospective Studies | 18 | 0.0 |
Anemia, Refractory/drug therapy | 2 | 66.0 |
Anemia, Refractory, with Excess of Blasts/drug therapy | 3 | 75.0 |
Male | 661 | 0.0 |
Middle Aged | 442 | 0.0 |
Myelodysplastic Syndromes/*drug therapy | 9 | 64.0 |
Prospective Studies | 58 | 1.0 |
Treatment Outcome | 42 | 1.0 |
Amino Acid Sequence | 39 | 0.0 |
Blotting, Western | 20 | 0.0 |
Cell Hypoxia/physiology | 3 | 4.0 |
Chromatography, Affinity | 7 | 0.0 |
DNA-Binding Proteins/*metabolism | 11 | 0.0 |
Molecular Sequence Data | 81 | 0.0 |
Mutagenesis, Site-Directed | 9 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Protein Binding | 18 | 0.0 |
*Receptors, Aryl Hydrocarbon | 3 | 11.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
Signal Transduction/*physiology | 4 | 0.0 |
Structure-Activity Relationship | 9 | 0.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Transcription Factors/genetics/metabolism/*physiology | 2 | 3.0 |
Blotting, Northern | 15 | 0.0 |
*Gene Expression Regulation, Neoplastic | 6 | 0.0 |
Immunohistochemistry | 20 | 0.0 |
Neoplasms/*physiopathology | 2 | 7.0 |
Reverse Transcriptase Polymerase Chain Reaction | 18 | 0.0 |
Anemia/complications/drug therapy | 3 | 100.0 |
Erythropoietin, Recombinant/therapeutic use | 10 | 62.0 |
Growth Substances/*therapeutic use | 3 | 23.0 |
Myelodysplastic Syndromes/complications/*drug therapy | 2 | 66.0 |
Adult | 444 | 0.0 |
Antigens, CD34 | 6 | 0.0 |
Blood Cell Count | 21 | 8.0 |
Colony-Forming Units Assay | 57 | 10.0 |
Comparative Study | 184 | 0.0 |
Hematopoietic Stem Cells/*pathology | 5 | 6.0 |
Bone Marrow Cells/pathology | 4 | 7.0 |
Erythrocyte Transfusion | 7 | 33.0 |
Erythropoietin/*blood | 210 | 97.0 |
Hemoglobins/analysis | 102 | 34.0 |
Logistic Models | 3 | 0.0 |
Prognosis | 27 | 0.0 |
Survival Rate | 7 | 0.0 |
Anoxia/physiopathology | 4 | 26.0 |
Erythropoietin/biosynthesis/*genetics | 9 | 69.0 |
Mice | 171 | 0.0 |
Mice, Inbred BALB C | 14 | 0.0 |
Nuclear Proteins/*metabolism | 4 | 0.0 |
Transcription Factors/*metabolism | 7 | 0.0 |
Vascular Endothelial Growth Factor A | 8 | 0.0 |
Vascular Endothelial Growth Factors | 8 | 0.0 |
Anemia/etiology/*physiopathology | 3 | 100.0 |
Blood Sedimentation | 3 | 1.0 |
Child | 73 | 0.0 |
Erythropoiesis/*physiology | 28 | 68.0 |
Erythropoietin/blood | 49 | 83.0 |
Receptors, Transferrin/blood | 9 | 47.0 |
Solubility | 13 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Adolescent | 122 | 0.0 |
*Bone Marrow Transplantation | 7 | 1.0 |
Cyclosporine/therapeutic use | 2 | 2.0 |
Drug Administration Schedule | 15 | 1.0 |
Erythropoietin, Recombinant/administration & dosage/*therapeutic use | 5 | 71.0 |
*Hematopoietic Stem Cell Transplantation | 3 | 0.0 |
Immunosuppressive Agents/therapeutic use | 9 | 4.0 |
Myelodysplastic Syndromes/therapy | 4 | 23.0 |
Age Factors | 11 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 4 | 0.0 |
Clinical Trials | 8 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use | 5 | 18.0 |
Risk Factors | 14 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 32 | 0.0 |
Reference Standards | 4 | 1.0 |
Sensitivity and Specificity | 35 | 1.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
Dizocilpine Maleate/pharmacology | 2 | 11.0 |
Erythropoietin/*metabolism/pharmacology | 2 | 50.0 |
Excitatory Amino Acid Antagonists/pharmacology | 2 | 6.0 |
Nicardipine/pharmacology | 2 | 28.0 |
Nitric Oxide/*metabolism | 4 | 3.0 |
Rats | 90 | 0.0 |
Rats, Wistar | 20 | 1.0 |
Hematopoietic Stem Cells/cytology/*drug effects | 5 | 9.0 |
Receptors, Erythropoietin/metabolism | 16 | 51.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 30 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 197 | 0.0 |
Blood Pressure/drug effects | 11 | 1.0 |
Calcium/*blood | 2 | 2.0 |
Creatinine/metabolism | 2 | 2.0 |
Cytosol/drug effects/metabolism | 2 | 9.0 |
Epoetin Alfa/*therapeutic use | 7 | 87.0 |
Hematinics/*therapeutic use | 6 | 85.0 |
Hematocrit | 150 | 38.0 |
Kidney Failure, Chronic/*blood/drug therapy | 2 | 100.0 |
Platelet Aggregation/drug effects | 3 | 1.0 |
Rats, Sprague-Dawley | 26 | 1.0 |
Signal Transduction | 25 | 0.0 |
Blood Preservation/methods | 2 | 22.0 |
Cold | 2 | 1.0 |
Hematopoietic Cell Growth Factors/pharmacology | 8 | 10.0 |
Hematopoietic Stem Cells/*cytology | 10 | 4.0 |
Interleukin-3/*pharmacology | 11 | 8.0 |
Interleukin-6/pharmacology | 7 | 2.0 |
Pregnancy | 50 | 0.0 |
Cell Division | 23 | 0.0 |
Cell Line | 73 | 0.0 |
Hydrolysis | 3 | 0.0 |
Indicators and Reagents | 2 | 0.0 |
Molecular Weight | 17 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
Acute Disease | 21 | 0.0 |
Altitude | 5 | 20.0 |
*Atmospheric Pressure | 3 | 16.0 |
Erythropoietin/*metabolism | 33 | 73.0 |
Renal Circulation | 2 | 5.0 |
Renal Dialysis/*adverse effects | 14 | 9.0 |
Chromosomes, Human, Pair 3 | 2 | 1.0 |
DNA Mutational Analysis | 5 | 0.0 |
Family Health | 3 | 0.0 |
Linkage (Genetics) | 5 | 0.0 |
Pedigree | 9 | 0.0 |
*Point Mutation | 2 | 0.0 |
Transcription Factors/metabolism | 9 | 0.0 |
*Tumor Suppressor Proteins | 7 | 0.0 |
*Ubiquitin-Protein Ligases | 7 | 1.0 |
Polycythemia/blood/*etiology | 4 | 100.0 |
RNA, Messenger/biosynthesis | 12 | 0.0 |
Anemia/*blood/etiology | 11 | 78.0 |
*Biological Assay | 2 | 9.0 |
Erythropoietin/*analysis/immunology | 2 | 100.0 |
Malaria/blood/*complications | 2 | 66.0 |
Mice, Inbred C57BL | 18 | 0.0 |
*Plasmodium chabaudi | 2 | 50.0 |
Erythrocyte Volume | 5 | 25.0 |
Polycythemia Vera/*diagnosis | 4 | 80.0 |
Questionnaires | 3 | 0.0 |
Anemia/drug therapy | 6 | 60.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Drug Stability | 7 | 3.0 |
*Erythropoietin, Recombinant | 7 | 100.0 |
Osmolar Concentration | 10 | 1.0 |
Case-Control Studies | 26 | 0.0 |
Cell Culture Techniques | 3 | 0.0 |
Cell Division/drug effects | 35 | 0.0 |
Collagen | 2 | 1.0 |
Cytokines/*pharmacology | 7 | 1.0 |
Erythroid Progenitor Cells/*pathology | 6 | 60.0 |
Methylcellulose | 2 | 25.0 |
Erythroid Progenitor Cells/drug effects/metabolism | 2 | 50.0 |
Gene Expression Regulation/drug effects | 8 | 0.0 |
Animals, Newborn | 3 | 0.0 |
Collagen/metabolism | 2 | 0.0 |
Drug Combinations | 4 | 0.0 |
Erythropoietin/*pharmacology | 53 | 48.0 |
Flow Cytometry | 19 | 0.0 |
Phenotype | 5 | 0.0 |
Recombinant Proteins/metabolism | 13 | 0.0 |
Erythropoietin/*analysis | 17 | 94.0 |
Polycythemia/blood/*diagnosis | 5 | 100.0 |
Predictive Value of Tests | 15 | 0.0 |
*Renal Dialysis | 63 | 14.0 |
Administration, Oral | 9 | 0.0 |
Cost-Benefit Analysis | 8 | 7.0 |
Health Care Costs | 2 | 7.0 |
Infusions, Intravenous | 6 | 0.0 |
Analysis of Variance | 21 | 1.0 |
Anemia/blood/*drug therapy | 5 | 100.0 |
Erythropoietin/analysis | 2 | 50.0 |
Infusion Pumps | 2 | 7.0 |
Insulin-Like Growth Factor I/analysis | 2 | 1.0 |
Anemia/blood/*drug therapy/etiology | 11 | 91.0 |
Blood Transfusion | 27 | 14.0 |
Bone Marrow/pathology | 25 | 6.0 |
Erythroid Progenitor Cells/pathology | 12 | 52.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 10 | 2.0 |
Kidney Failure, Chronic/complications/therapy | 8 | 30.0 |
Leukemia, Erythroblastic, Acute/pathology | 5 | 16.0 |
Recombinant Proteins/immunology/therapeutic use | 2 | 20.0 |
Renal Dialysis | 33 | 10.0 |
Tumor Cells, Cultured/drug effects | 3 | 0.0 |
DNA/metabolism | 8 | 0.0 |
Erythropoiesis | 33 | 43.0 |
Gene Expression | 23 | 0.0 |
Mice, Knockout | 3 | 0.0 |
Severity of Illness Index | 15 | 1.0 |
Aging/*blood | 5 | 7.0 |
Creatinine/blood | 24 | 7.0 |
Reference Values | 60 | 1.0 |
Antigens, CD34/biosynthesis | 2 | 2.0 |
Cell Differentiation | 17 | 0.0 |
Cell Lineage | 5 | 1.0 |
Cytokines/*metabolism | 2 | 0.0 |
Erythropoietin/metabolism | 8 | 32.0 |
Erythropoietin/*biosynthesis | 43 | 100.0 |
Glomerular Filtration Rate | 3 | 2.0 |
Angiotensin-Converting Enzyme Inhibitors/*pharmacology | 4 | 2.0 |
Antihypertensive Agents/*pharmacology | 2 | 4.0 |
Kidney Transplantation/*adverse effects | 9 | 15.0 |
Losartan/*pharmacology | 3 | 37.0 |
Anemia/blood/*complications | 2 | 100.0 |
Anoxia/blood/*physiopathology | 2 | 66.0 |
Erythropoietin/*blood/deficiency | 3 | 100.0 |
Kidney Failure, Chronic/*blood | 7 | 10.0 |
Proteinuria | 2 | 5.0 |
Apoptosis/drug effects | 2 | 0.0 |
Cell Culture Techniques/methods | 4 | 1.0 |
Cell Differentiation/drug effects | 15 | 1.0 |
Erythropoiesis/*drug effects | 28 | 58.0 |
Tumor Stem Cells/pathology | 2 | 6.0 |
Erythropoietin/*biosynthesis/blood | 15 | 100.0 |
Neoplasms/*drug therapy | 3 | 2.0 |
Tumor Necrosis Factor-alpha/*metabolism | 3 | 0.0 |
Anemia/blood | 16 | 64.0 |
Carnitine/*therapeutic use | 2 | 33.0 |
Lipids/blood | 5 | 0.0 |
Randomized Controlled Trials | 5 | 1.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
Rabbits | 14 | 0.0 |
Anemia/metabolism | 4 | 80.0 |
Enzyme Inhibitors/*pharmacology | 3 | 0.0 |
Gene Expression/drug effects | 5 | 0.0 |
NG-Nitroarginine Methyl Ester/pharmacology | 2 | 4.0 |
Oxygen/metabolism | 8 | 3.0 |
RNA, Messenger/analysis | 13 | 0.0 |
omega-N-Methylarginine/*pharmacology | 2 | 100.0 |
Kidney/metabolism | 13 | 3.0 |
Kidney Failure, Chronic/*complications/therapy | 9 | 47.0 |
Ammonia/*pharmacology | 2 | 40.0 |
Biological Transport, Active/drug effects | 2 | 3.0 |
Glucose/metabolism | 2 | 0.0 |
Glycosylation/drug effects | 2 | 6.0 |
N-Acetylneuraminic Acid/analysis | 4 | 57.0 |
DNA-Binding Proteins/metabolism | 7 | 0.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Nuclear Proteins/metabolism | 3 | 0.0 |
Sex Factors | 8 | 0.0 |
Disease Models, Animal | 12 | 0.0 |
Drug Interactions | 9 | 0.0 |
Antineoplastic Agents/*adverse effects | 6 | 11.0 |
Erythropoietin/biosynthesis/*blood | 12 | 100.0 |
Hemoglobins/metabolism | 65 | 41.0 |
Neoplasms/*blood/complications/drug therapy | 2 | 100.0 |
Child, Preschool | 42 | 0.0 |
*Kidney Transplantation | 12 | 2.0 |
Anemia, Neonatal/*drug therapy | 2 | 100.0 |
Erythropoietin/administration & dosage/*therapeutic use | 12 | 85.0 |
Ferritin/blood | 45 | 28.0 |
Gestational Age | 17 | 1.0 |
*Infant, Premature | 4 | 7.0 |
Biopsy | 4 | 0.0 |
Blood Proteins/metabolism | 6 | 2.0 |
Eosinophil Granule Proteins | 17 | 7.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
*Ribonucleases | 15 | 7.0 |
*Environmental Exposure | 2 | 2.0 |
Infant | 31 | 0.0 |
Lead Poisoning/*physiopathology | 2 | 66.0 |
Regression Analysis | 19 | 1.0 |
Anoxia/*metabolism | 6 | 11.0 |
Binding Sites | 15 | 0.0 |
*DNA Methylation | 2 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 5 | 0.0 |
Erythropoietin/*genetics | 29 | 85.0 |
Gene Expression Regulation | 14 | 0.0 |
Helix-Loop-Helix Motifs | 3 | 1.0 |
Nuclear Proteins/genetics/*metabolism | 3 | 0.0 |
Transcription Factors/genetics/*metabolism | 3 | 0.0 |
Blotting, Southern | 7 | 0.0 |
*Gene Expression | 8 | 0.0 |
*Milk Proteins | 8 | 1.0 |
Phosphorylation | 14 | 0.0 |
*Proto-Oncogene Proteins | 6 | 0.0 |
Area Under Curve | 4 | 0.0 |
Drug Therapy, Combination | 19 | 1.0 |
Erythropoietin/*administration & dosage | 13 | 72.0 |
Injections, Subcutaneous | 38 | 12.0 |
Uremia/blood/*therapy | 2 | 33.0 |
Base Sequence | 64 | 0.0 |
Cell Membrane/*metabolism | 2 | 0.0 |
Cercopithecus aethiops | 8 | 0.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Erythroid Progenitor Cells/metabolism | 3 | 23.0 |
Genes, Reporter | 8 | 0.0 |
Polymerase Chain Reaction | 21 | 0.0 |
Sequence Deletion | 6 | 0.0 |
Bronchoalveolar Lavage Fluid/cytology | 2 | 1.0 |
Cell Degranulation | 2 | 4.0 |
Eosinophilia/immunology | 2 | 40.0 |
Guinea Pigs | 3 | 0.0 |
In Vitro | 33 | 0.0 |
Circadian Rhythm/*physiology | 5 | 5.0 |
Myelodysplastic Syndromes/*blood | 4 | 36.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 4 | 0.0 |
Granulocyte Colony-Stimulating Factor/therapeutic use | 5 | 9.0 |
Immunosuppressive Agents/*therapeutic use | 2 | 1.0 |
Linear Models | 13 | 2.0 |
Receptors, Transferrin/*blood | 5 | 35.0 |
Anemia/blood/epidemiology/*etiology | 3 | 100.0 |
Iron/blood | 24 | 24.0 |
Statistics, Nonparametric | 6 | 0.0 |
Transferrin/analysis | 10 | 11.0 |
*Anoxia | 2 | 7.0 |
Cell Line, Tumor | 4 | 0.0 |
Dimerization | 7 | 0.0 |
Enhancer Elements (Genetics) | 5 | 1.0 |
Erythropoietin/*biosynthesis/genetics | 19 | 90.0 |
Luciferases/metabolism | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Nuclear Proteins/metabolism/*physiology | 2 | 6.0 |
Plasmids/metabolism | 2 | 0.0 |
Transcription Factors/metabolism/*physiology | 2 | 2.0 |
Transcription, Genetic | 11 | 0.0 |
Vascular Endothelial Growth Factor A/metabolism | 2 | 1.0 |
Calcium/metabolism | 3 | 0.0 |
Cell Adhesion | 3 | 0.0 |
Eosinophil Peroxidase | 36 | 62.0 |
Ionophores/pharmacology | 2 | 1.0 |
Spectrum Analysis | 2 | 3.0 |
Cross-Sectional Studies | 12 | 0.0 |
Injections, Intravenous | 26 | 4.0 |
Biological Markers/blood | 23 | 1.0 |
Probability | 6 | 0.0 |
Receptors, Transferrin/analysis/*blood | 2 | 100.0 |
Lipoproteins/blood | 3 | 0.0 |
Anemia/*drug therapy/etiology | 24 | 80.0 |
Erythrocyte Count | 29 | 31.0 |
Reticulocyte Count | 21 | 60.0 |
Carcinoma, Hepatocellular | 16 | 4.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Liver Neoplasms | 13 | 4.0 |
Phenanthridines/pharmacology | 2 | 10.0 |
Protein Kinase C/antagonists & inhibitors/metabolism | 2 | 2.0 |
Electroporation/*methods | 3 | 21.0 |
*Gene Transfer Techniques | 13 | 3.0 |
Injections, Intramuscular | 12 | 7.0 |
Ligands | 7 | 0.0 |
Plasmids | 8 | 0.0 |
Thigh | 2 | 7.0 |
Anemia/*blood/drug therapy/etiology | 3 | 100.0 |
Erythrocyte Indices | 13 | 20.0 |
Erythrocytes | 2 | 4.0 |
Recombinant Proteins/therapeutic use | 85 | 24.0 |
Anemia/blood/*chemically induced | 2 | 66.0 |
Antineoplastic Agents/adverse effects/therapeutic use | 2 | 25.0 |
Hemoglobins/analysis/drug effects | 3 | 37.0 |
Gene Therapy/*methods | 9 | 2.0 |
Doping in Sports/*prevention & control | 3 | 100.0 |
Immunoassay/methods | 2 | 3.0 |
Reagent Kits, Diagnostic | 3 | 2.0 |
Reproducibility of Results | 10 | 0.0 |
Granulocyte Colony-Stimulating Factor/*therapeutic use | 4 | 6.0 |
Stem Cells/*cytology | 2 | 2.0 |
Circadian Rhythm | 9 | 3.0 |
Confidence Intervals | 4 | 1.0 |
Erythropoietin, Recombinant/*administration & dosage/therapeutic use | 2 | 100.0 |
European Continental Ancestry Group | 2 | 0.0 |
Iron/administration & dosage | 4 | 80.0 |
Eosinophils/*drug effects/secretion | 2 | 100.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Interleukin-2/*pharmacology | 3 | 1.0 |
Stimulation, Chemical | 7 | 1.0 |
Erythropoietin/blood/genetics | 2 | 66.0 |
Lentivirus/*genetics | 2 | 5.0 |
Macrophages/metabolism | 2 | 0.0 |
Mice, SCID | 6 | 0.0 |
Cytokines/*blood | 4 | 1.0 |
Hemoglobinometry | 7 | 22.0 |
Interleukin-1/blood | 2 | 1.0 |
Interleukin-6/blood | 10 | 2.0 |
Tumor Necrosis Factor-alpha/analysis | 6 | 1.0 |
Gene Dosage | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
*Gene Therapy | 4 | 1.0 |
*Transcription Factors | 10 | 0.0 |
*Erythropoietin | 2 | 100.0 |
Intestinal Absorption | 5 | 3.0 |
Milk/metabolism | 2 | 33.0 |
Epoetin Alfa/administration & dosage/*therapeutic use | 2 | 100.0 |
Erythropoiesis/drug effects | 24 | 57.0 |
Hematinics/administration & dosage/*therapeutic use | 2 | 100.0 |
Hemoglobins/drug effects | 6 | 40.0 |
Neoplasms/*complications/drug therapy | 3 | 60.0 |
Practice Guidelines | 2 | 2.0 |
Neuroprotective Agents/pharmacology | 2 | 5.0 |
Angiotensin-Converting Enzyme Inhibitors/therapeutic use | 3 | 2.0 |
Cohort Studies | 8 | 0.0 |
Erythropoietin/therapeutic use | 10 | 71.0 |
Brain/metabolism | 4 | 0.0 |
Erythropoietin/*physiology | 18 | 78.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
*Cell Transformation, Neoplastic | 3 | 0.0 |
Enzyme Activation | 6 | 0.0 |
Erythroblasts/cytology | 3 | 100.0 |
*Erythropoiesis | 31 | 46.0 |
Receptors, Erythropoietin/*metabolism | 7 | 41.0 |
Stress | 2 | 3.0 |
Anemia/*drug therapy/*etiology | 8 | 100.0 |
Diabetic Nephropathies/physiopathology | 2 | 13.0 |
Transferrin/*metabolism | 3 | 5.0 |
Anemia/etiology/*therapy | 13 | 86.0 |
Erythropoietin, Recombinant/*administration & dosage | 11 | 91.0 |
Splenomegaly/etiology | 2 | 11.0 |
Bone Marrow/metabolism | 7 | 6.0 |
Cell Count | 11 | 1.0 |
Cytokines/metabolism | 4 | 0.0 |
Erythroid Progenitor Cells/cytology | 5 | 18.0 |
Receptor, Angiotensin, Type 1 | 2 | 1.0 |
Receptor, Angiotensin, Type 2 | 2 | 2.0 |
Anemia/etiology | 10 | 32.0 |
Cell Hypoxia | 20 | 12.0 |
Mice, Nude | 6 | 0.0 |
Recombinant Proteins/pharmacology | 52 | 2.0 |
Carcinoma, Hepatocellular/genetics/*metabolism | 2 | 12.0 |
DNA Primers/chemistry | 4 | 0.0 |
Liver Neoplasms/genetics/*metabolism | 2 | 14.0 |
*Signal Transduction | 11 | 0.0 |
Glycosylation | 11 | 1.0 |
Kidney Failure, Chronic/blood/*therapy | 10 | 47.0 |
Molecular Structure | 2 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Genetic Vectors/*genetics | 3 | 4.0 |
Erythropoietin, Recombinant/*pharmacology | 11 | 47.0 |
Models, Biological | 5 | 0.0 |
Neurons/*drug effects/pathology | 2 | 22.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Erythropoietin/genetics | 4 | 28.0 |
*Genetic Vectors | 6 | 1.0 |
*Membrane Glycoproteins | 2 | 0.0 |
Muscle, Skeletal/*metabolism | 4 | 2.0 |
Species Specificity | 13 | 0.0 |
Transduction, Genetic | 5 | 1.0 |
Anemia/complications/*drug therapy | 7 | 100.0 |
Chi-Square Distribution | 3 | 0.0 |
Follow-Up Studies | 23 | 0.0 |
Hysterectomy | 2 | 2.0 |
Length of Stay | 2 | 2.0 |
Postoperative Period | 5 | 1.0 |
Preoperative Care | 4 | 2.0 |
Platelet Count | 17 | 3.0 |
Polycythemia Vera/*blood | 5 | 71.0 |
Thrombopoietin/*blood | 5 | 5.0 |
Anemia/*etiology | 7 | 77.0 |
Hemoglobins | 8 | 26.0 |
Intensive Care Units | 3 | 5.0 |
Iron/*blood | 10 | 25.0 |
Epitopes | 2 | 0.0 |
Blood Proteins/*analysis | 3 | 2.0 |
Eosinophil-Derived Neurotoxin | 9 | 11.0 |
Peroxidases/*analysis | 2 | 18.0 |
Blood Proteins/analysis | 4 | 2.0 |
Bronchial Provocation Tests | 2 | 2.0 |
Disease Progression | 7 | 0.0 |
Double-Blind Method | 26 | 1.0 |
Inflammation | 4 | 1.0 |
Leukocyte Count | 17 | 1.0 |
Peroxidases/blood | 4 | 36.0 |
Skin Tests | 2 | 1.0 |
RNA, Messenger/genetics/metabolism | 10 | 0.0 |
Alleles | 2 | 0.0 |
Blood Donors | 5 | 2.0 |
Electrophoresis, Polyacrylamide Gel | 14 | 0.0 |
Gene Frequency | 4 | 0.0 |
*Hematocrit | 5 | 33.0 |
Receptors, Erythropoietin/*genetics | 7 | 26.0 |
Hematologic Diseases/*drug therapy | 2 | 50.0 |
Anemia/*physiopathology | 2 | 100.0 |
Erythroid Progenitor Cells/*physiology | 5 | 38.0 |
Hemoglobins/*metabolism | 6 | 14.0 |
Polycythemia/metabolism | 3 | 100.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Restriction Mapping | 9 | 0.0 |
Sequence Homology | 2 | 0.0 |
Swine/*genetics | 2 | 1.0 |
Injections, Intradermal | 2 | 4.0 |
Kidney Failure, Chronic/therapy | 5 | 14.0 |
Peritoneal Dialysis | 3 | 8.0 |
Protein Conformation | 12 | 0.0 |
Fluorescent Antibody Technique | 5 | 0.0 |
Depression, Chemical | 3 | 1.0 |
Drug Synergism | 8 | 0.0 |
Erythropoietin/*administration & dosage/therapeutic use | 5 | 100.0 |
Biological Assay | 6 | 2.0 |
Circular Dichroism | 2 | 0.0 |
Escherichia coli | 4 | 0.0 |
Heat | 3 | 0.0 |
Temperature | 6 | 0.0 |
Binding, Competitive | 7 | 0.0 |
Erythropoiesis/genetics/*physiology | 2 | 66.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Erythropoietin/blood/*deficiency | 6 | 100.0 |
Heart Rate/physiology | 3 | 3.0 |
Blood Pressure | 6 | 0.0 |
Diabetic Nephropathies/*blood | 2 | 10.0 |
Cytomegalovirus/genetics | 3 | 3.0 |
*Electroporation | 2 | 33.0 |
Gene Deletion | 2 | 0.0 |
Genetic Vectors/administration & dosage | 2 | 6.0 |
Mice, Mutant Strains | 2 | 0.0 |
Transgenes | 3 | 0.0 |
Comorbidity | 4 | 1.0 |
Anemia/prevention & control | 3 | 75.0 |
Kidney Transplantation/immunology | 2 | 3.0 |
Peritoneal Dialysis, Continuous Ambulatory | 8 | 18.0 |
Kinetics | 46 | 0.0 |
Multivariate Analysis | 4 | 0.0 |
*Adaptation, Physiological | 4 | 7.0 |
Brain/*metabolism | 3 | 0.0 |
*Gene Expression Regulation | 15 | 0.0 |
Kidney/pathology | 4 | 2.0 |
Mice, Inbred ICR | 8 | 3.0 |
Erythropoietin, Recombinant/adverse effects/*therapeutic use | 3 | 75.0 |
Kidney Failure, Chronic/*complications | 15 | 39.0 |
Diagnosis, Differential | 13 | 0.0 |
Folic Acid/blood | 4 | 4.0 |
Vitamin B 12/blood | 5 | 5.0 |
Arthritis, Rheumatoid/*complications | 4 | 26.0 |
Substance-Related Disorders/*diagnosis | 2 | 100.0 |
Anemia/*chemically induced | 4 | 80.0 |
Angiotensin-Converting Enzyme Inhibitors/*adverse effects | 2 | 4.0 |
Erythropoietin/biosynthesis | 6 | 66.0 |
Erythropoietin, Recombinant/administration & dosage | 2 | 66.0 |
*Polymorphism, Genetic | 3 | 0.0 |
*Renal Dialysis/adverse effects | 3 | 13.0 |
Antibodies/blood | 2 | 3.0 |
Erythropoietin/*administration & dosage/*analogs & derivatives | 2 | 66.0 |
Red-Cell Aplasia, Pure/*chemically induced/immunology | 2 | 100.0 |
Oxygen/blood | 11 | 9.0 |
Splenectomy | 2 | 3.0 |
Drug Evaluation | 3 | 1.0 |
Granulocyte Colony-Stimulating Factor/administration & dosage | 4 | 14.0 |
Interleukin-3/administration & dosage | 3 | 50.0 |
Anemia/drug therapy/etiology | 7 | 58.0 |
Kidney Failure, Chronic/complications/*drug therapy | 2 | 50.0 |
Body Weight/drug effects | 6 | 3.0 |
Recombinant Proteins | 33 | 4.0 |
Kidney Failure, Chronic/*drug therapy | 2 | 25.0 |
Anemia/blood/*etiology | 7 | 77.0 |
*Gene Expression Regulation/drug effects | 3 | 1.0 |
Genetic Vectors/genetics | 3 | 1.0 |
Immunoblotting | 3 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Simian virus 40/genetics | 2 | 1.0 |
Eosinophils/*enzymology | 10 | 83.0 |
Oxidation-Reduction | 8 | 0.0 |
Substrate Specificity | 2 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Nuclear Proteins/genetics | 2 | 0.0 |
Anoxia/metabolism | 6 | 15.0 |
Cell Survival/drug effects | 10 | 0.0 |
Erythropoietin/genetics/*metabolism | 6 | 75.0 |
Protein Binding/drug effects | 3 | 0.0 |
Polycythemia/*etiology | 6 | 85.0 |
Angiotensin-Converting Enzyme Inhibitors/pharmacology | 2 | 2.0 |
*Kidney Transplantation/adverse effects | 2 | 18.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Erythropoietin/pharmacology | 35 | 27.0 |
DNA Primers/genetics | 2 | 0.0 |
Milk, Human/*metabolism | 2 | 18.0 |
Erythroid Progenitor Cells/*drug effects | 6 | 46.0 |
Erythropoietin, Recombinant/pharmacology | 4 | 50.0 |
Liposomes | 3 | 1.0 |
Liver/metabolism | 6 | 0.0 |
Macrophages/*physiology | 3 | 3.0 |
Phlebotomy | 10 | 41.0 |
Fetus/*physiology | 2 | 5.0 |
Receptors, Erythropoietin/physiology | 5 | 71.0 |
Aging/*physiology | 3 | 1.0 |
Embryonic and Fetal Development/physiology | 3 | 3.0 |
Gene Expression Regulation, Developmental | 3 | 0.0 |
Culture Media, Serum-Free | 5 | 1.0 |
Hematopoietic Stem Cells/cytology/*drug effects/immunology | 2 | 25.0 |
Thrombopoietin/*pharmacology | 5 | 5.0 |
Heterozygote | 5 | 0.0 |
Pregnancy Complications, Hematologic/*blood | 4 | 25.0 |
beta-Thalassemia/*blood | 3 | 27.0 |
Aldosterone/blood | 3 | 1.0 |
Atrial Natriuretic Factor/blood | 4 | 4.0 |
Blood Pressure/*drug effects | 7 | 4.0 |
Blood Viscosity/drug effects | 2 | 15.0 |
Renin/blood | 12 | 3.0 |
Erythropoietin, Recombinant/pharmacology/*therapeutic use | 3 | 60.0 |
Iron/*metabolism | 5 | 3.0 |
Anoxia | 5 | 6.0 |
Binding Sites/genetics | 2 | 0.0 |
DNA/genetics/metabolism | 4 | 1.0 |
Nitric Oxide/metabolism | 2 | 1.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Embryonic and Fetal Development | 3 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 2 | 0.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Transcription Factors/genetics/metabolism | 3 | 0.0 |
Interleukin-11/blood | 2 | 15.0 |
Lymphokines/blood | 3 | 5.0 |
Thrombopoietin/blood | 2 | 15.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors | 2 | 2.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
Protein Kinase C/metabolism/*physiology | 2 | 20.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Biological Markers/analysis | 2 | 0.0 |
False Positive Reactions | 2 | 0.0 |
Immunoassay | 2 | 0.0 |
Substance Abuse Detection/*methods | 4 | 66.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Erythroid Progenitor Cells/drug effects/*physiology | 3 | 75.0 |
Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors | 2 | 4.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
Proto-Oncogene Proteins/metabolism | 5 | 0.0 |
Stem Cell Factor/*pharmacology | 2 | 3.0 |
Adaptation, Physiological | 3 | 3.0 |
*Blood Physiology | 2 | 7.0 |
Erythrocytes/cytology | 5 | 21.0 |
Biological Markers | 5 | 0.0 |
Thailand | 4 | 2.0 |
Anoxia/*physiopathology | 5 | 12.0 |
Carbon Dioxide/blood | 3 | 8.0 |
Antibodies/pharmacology | 3 | 0.0 |
Autocrine Communication | 2 | 2.0 |
Erythroid Progenitor Cells/*cytology/drug effects | 2 | 33.0 |
Glycophorin/biosynthesis | 2 | 28.0 |
Receptors, Erythropoietin/genetics/*metabolism | 4 | 33.0 |
*Altitude | 10 | 16.0 |
C-Reactive Protein/analysis | 5 | 0.0 |
Leptin/*blood | 3 | 3.0 |
*Peritoneal Dialysis | 7 | 11.0 |
Radioimmunoassay | 52 | 2.0 |
Apoptosis | 8 | 0.0 |
Blood Gas Analysis | 6 | 15.0 |
Recombinant Proteins/blood | 4 | 26.0 |
Reticulocytes/cytology | 3 | 50.0 |
Bone Marrow/drug effects | 4 | 5.0 |
Blood Volume/*physiology | 2 | 18.0 |
Intraoperative Period | 2 | 3.0 |
Cytokines/blood | 6 | 2.0 |
Exercise/*physiology | 3 | 0.0 |
Neopterin/blood | 2 | 7.0 |
Plasma Volume | 5 | 15.0 |
Running/*physiology | 2 | 5.0 |
Antibodies/immunology | 5 | 1.0 |
Antibody Specificity | 2 | 0.0 |
Cross Reactions | 5 | 0.0 |
Erythropoietin/*immunology | 3 | 75.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Neurons/metabolism | 2 | 0.0 |
Enzyme Induction/drug effects | 3 | 0.0 |
Erythropoietin, Recombinant/metabolism/*pharmacology | 2 | 66.0 |
Receptors, Erythropoietin/genetics | 3 | 33.0 |
Antihypertensive Agents/pharmacology | 2 | 4.0 |
Kidney Transplantation/*physiology | 7 | 14.0 |
Pregnancy/*blood | 8 | 5.0 |
Pregnancy Complications, Hematologic | 2 | 28.0 |
Immunoglobulin G | 2 | 1.0 |
Radioimmunoassay/methods | 8 | 5.0 |
Bone Marrow Cells/cytology | 2 | 2.0 |
Dependovirus/genetics | 2 | 6.0 |
Amniotic Fluid/*chemistry | 5 | 10.0 |
Erythropoietin/*adverse effects | 5 | 100.0 |
Kidney Failure, Chronic/*therapy | 5 | 38.0 |
Creatinine/*blood | 2 | 12.0 |
Kidney Transplantation/immunology/*physiology | 5 | 26.0 |
Monitoring, Physiologic | 3 | 3.0 |
Anemia/etiology/*metabolism | 2 | 100.0 |
Erythropoiesis/physiology | 10 | 55.0 |
Erythroid Progenitor Cells/*cytology | 6 | 31.0 |
Staining and Labeling | 2 | 0.0 |
Hydroxyurea/therapeutic use | 2 | 16.0 |
Interferon-alpha/therapeutic use | 2 | 5.0 |
Prolactin/blood | 2 | 0.0 |
Erythropoietin/*blood/immunology | 4 | 100.0 |
Deferoxamine/pharmacology | 5 | 11.0 |
Erythropoietin/blood/*secretion | 2 | 100.0 |
Erythropoietin/blood/*physiology | 2 | 100.0 |
Granulocyte Colony-Stimulating Factor/*administration & dosage | 5 | 18.0 |
Remission Induction | 6 | 1.0 |
*Infant, Low Birth Weight | 2 | 9.0 |
Bone Marrow Cells/*metabolism | 2 | 4.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 5 | 3.0 |
Interleukin-3/pharmacology | 23 | 8.0 |
Ferritin/*blood | 5 | 7.0 |
Kidney/physiopathology | 4 | 6.0 |
Liver Cirrhosis/*blood | 4 | 11.0 |
*Fetal Blood | 4 | 8.0 |
Cell Nucleus/metabolism | 5 | 0.0 |
Culture Media/pharmacology | 4 | 4.0 |
Erythropoietin/*analysis/pharmacology | 3 | 100.0 |
Receptors, Erythropoietin/genetics/metabolism | 4 | 36.0 |
Tumor Necrosis Factor-alpha/pharmacology | 4 | 0.0 |
Kidney Failure, Chronic/*blood/therapy | 7 | 12.0 |
Parathyroid Hormone/*blood | 3 | 3.0 |
Anoxia/blood | 5 | 55.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 2 | 0.0 |
Hypertension/chemically induced | 4 | 33.0 |
Androgens/*therapeutic use | 2 | 40.0 |
Nandrolone/*analogs & derivatives/therapeutic use | 2 | 100.0 |
Gene Therapy | 2 | 0.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Diabetes Complications | 2 | 1.0 |
Delivery, Obstetric | 2 | 5.0 |
Fetal Blood/*chemistry | 6 | 10.0 |
Erythropoietin/blood/*metabolism | 4 | 100.0 |
Exercise Test | 2 | 0.0 |
Plasma Volume/*physiology | 3 | 27.0 |
Erythropoietin/*cerebrospinal fluid | 2 | 66.0 |
Biotechnology | 2 | 7.0 |
Culture Media | 13 | 1.0 |
Cobalt/pharmacology | 9 | 18.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
*Enhancer Elements (Genetics) | 4 | 1.0 |
Nuclear Proteins/genetics/metabolism | 2 | 1.0 |
Spleen Focus-Forming Viruses/*physiology | 2 | 100.0 |
Erythropoietin/chemistry/*metabolism | 2 | 66.0 |
Forecasting | 3 | 0.0 |
Heart Rate/drug effects | 2 | 0.0 |
Adrenergic beta-Agonists/*pharmacology | 3 | 13.0 |
Cross-Over Studies | 7 | 1.0 |
Fenoterol/*pharmacology | 2 | 66.0 |
Immunoenzyme Techniques | 8 | 0.0 |
Insulin-Like Growth Factor I/*pharmacology | 2 | 1.0 |
Erythrocytes/physiology | 2 | 5.0 |
Hematopoietic Stem Cells/physiology | 2 | 4.0 |
Oxygen/*blood | 7 | 15.0 |
Oxygen Consumption/*physiology | 2 | 6.0 |
Alkaline Phosphatase/metabolism | 2 | 1.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Fibrosarcoma/metabolism | 2 | 16.0 |
Interferon-alpha/*metabolism | 2 | 8.0 |
Interferon-beta/*metabolism | 2 | 16.0 |
Receptors, Interferon/genetics/*metabolism | 2 | 33.0 |
Erythrocyte Membrane/*metabolism | 2 | 2.0 |
Kidney Failure, Chronic/blood/complications/*therapy | 3 | 60.0 |
Cloning, Molecular | 17 | 0.0 |
Erythropoietin/physiology | 4 | 33.0 |
Mutagenesis | 4 | 0.0 |
Blood Proteins/*metabolism | 3 | 1.0 |
Immunoglobulin E/blood | 5 | 3.0 |
Peroxidases/*metabolism | 2 | 7.0 |
Respiratory Function Tests | 4 | 2.0 |
Injections, Intraperitoneal | 6 | 4.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 13 | 12.0 |
Erythroid Progenitor Cells/cytology/drug effects | 2 | 20.0 |
Fetal Blood/cytology | 4 | 2.0 |
*Hematopoiesis | 11 | 5.0 |
Transplantation, Heterologous | 2 | 0.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
Uremia/*blood/therapy | 3 | 17.0 |
*Blood Transfusion | 9 | 8.0 |
Lung Neoplasms/*drug therapy | 2 | 4.0 |
Anemia/blood/etiology | 10 | 76.0 |
Erythropoiesis/*drug effects/physiology | 4 | 80.0 |
Kidney Failure, Chronic/*blood/complications | 2 | 25.0 |
Culture Techniques | 4 | 0.0 |
Anoxia/genetics/metabolism | 3 | 75.0 |
Interleukin-1/*pharmacology | 3 | 0.0 |
Serum Albumin/analysis | 4 | 2.0 |
*Homeostasis | 2 | 3.0 |
Recurrence | 2 | 0.0 |
Transferrin/metabolism | 7 | 4.0 |
Cell Separation | 9 | 0.0 |
Fetus | 5 | 0.0 |
Hematopoiesis/drug effects | 10 | 12.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 3 | 4.0 |
Infant, Premature/*blood | 4 | 12.0 |
Pregnancy Trimester, Second | 2 | 0.0 |
Pregnancy Trimester, Third | 2 | 1.0 |
Reticulocyte Count/drug effects | 2 | 50.0 |
Chelating Agents/pharmacology | 3 | 3.0 |
Partial Pressure | 7 | 14.0 |
Culture Media, Conditioned | 6 | 1.0 |
Stem Cell Factor/pharmacology | 3 | 2.0 |
Apolipoproteins/blood | 2 | 0.0 |
Uremia/blood/therapy | 2 | 28.0 |
Cell Degranulation/*physiology | 2 | 40.0 |
Eosinophils/*immunology | 4 | 6.0 |
Erythropoietin/*chemistry | 2 | 50.0 |
Receptors, Erythropoietin/chemistry/genetics/*metabolism | 2 | 100.0 |
Health Services for the Aged/economics/*utilization | 2 | 50.0 |
Hospitalization/economics | 2 | 28.0 |
Japan | 2 | 0.0 |
Evaluation Studies | 7 | 1.0 |
Erythropoietin/*blood/metabolism | 3 | 75.0 |
Anemia/blood/*drug therapy/*etiology | 3 | 100.0 |
Erythropoietin/deficiency | 2 | 100.0 |
Cell Hypoxia/*physiology | 2 | 3.0 |
Endothelial Growth Factors/*genetics | 2 | 1.0 |
*Gene Expression Regulation, Neoplastic/drug effects | 2 | 3.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Lymphokines/*genetics | 2 | 0.0 |
Thapsigargin/pharmacology | 2 | 1.0 |
Sequence Analysis | 4 | 1.0 |
Cycloheximide/pharmacology | 4 | 0.0 |
Oxygen/*metabolism | 6 | 4.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
Biological Transport | 4 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
Calcium/*metabolism | 2 | 0.0 |
Anemia/*drug therapy/etiology/*physiopathology | 2 | 100.0 |
Transplantation, Homologous | 10 | 1.0 |
Fetal Blood/chemistry | 2 | 3.0 |
Pregnancy, Multiple | 2 | 1.0 |
Interleukin-6/*blood | 2 | 0.0 |
Erythropoietin, Recombinant/*chemistry | 2 | 100.0 |
Microscopy, Electron, Scanning | 3 | 1.0 |
Microspheres | 3 | 1.0 |
Erythropoietin, Recombinant/*pharmacokinetics/*pharmacology | 2 | 100.0 |
Iodine Radioisotopes | 10 | 2.0 |
Receptors, Erythropoietin/*physiology | 3 | 21.0 |
Tritium | 3 | 1.0 |
Antineoplastic Agents/*therapeutic use | 3 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Oxygen/physiology | 2 | 15.0 |
Acquired Immunodeficiency Syndrome/complications | 2 | 4.0 |
Kidney Failure, Chronic/complications | 10 | 50.0 |
Mice, Inbred C3H | 4 | 0.0 |
Mice, Inbred DBA | 5 | 1.0 |
Neoplasms/complications | 5 | 27.0 |
Crystallography, X-Ray | 2 | 0.0 |
Models, Molecular | 4 | 0.0 |
*Molecular Mimicry | 2 | 5.0 |
Tretinoin/*therapeutic use | 2 | 9.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*therapeutic use | 2 | 7.0 |
Myelodysplastic Syndromes/*complications | 5 | 45.0 |
Blood Physiology | 3 | 4.0 |
Kidney Failure, Chronic/blood/*physiopathology | 2 | 33.0 |
Polycythemia/*physiopathology | 5 | 83.0 |
Histamine Release | 2 | 3.0 |
Peroxidases/*blood | 4 | 23.0 |
Amniotic Fluid/metabolism | 4 | 12.0 |
Fetal Anoxia/diagnosis | 2 | 100.0 |
Fetal Blood/metabolism | 2 | 3.0 |
ROC Curve | 2 | 1.0 |
Antibodies/analysis | 5 | 3.0 |
Interleukin-3/therapeutic use | 2 | 33.0 |
Interleukin-6/therapeutic use | 2 | 50.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 4 | 3.0 |
Microscopy, Confocal | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Cyclic GMP/analogs & derivatives/pharmacology | 2 | 25.0 |
Nitroprusside/pharmacology | 2 | 2.0 |
Transfection/genetics | 2 | 1.0 |
Anemia/*chemically induced/*drug therapy | 2 | 100.0 |
Pilot Projects | 6 | 0.0 |
Liver/*metabolism | 6 | 1.0 |
Receptors, Tumor Necrosis Factor, Type I | 2 | 0.0 |
Erythrocyte Aging | 3 | 9.0 |
Erythrocyte Deformability | 2 | 22.0 |
Erythropoiesis/drug effects/*physiology | 3 | 42.0 |
Maze Learning/*drug effects | 2 | 50.0 |
Rats, Inbred F344 | 4 | 1.0 |
Anemia, Aplastic/*pathology | 2 | 13.0 |
Breast Neoplasms/*blood/*drug therapy/pathology | 2 | 100.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Doxorubicin/administration & dosage | 2 | 1.0 |
Erythropoietin/analysis/*blood | 2 | 66.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
Methotrexate/administration & dosage | 2 | 2.0 |
Neoplasm Staging | 5 | 0.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
Dependovirus/*genetics | 3 | 3.0 |
Antigens, CD34/metabolism | 3 | 1.0 |
Hematopoiesis | 6 | 2.0 |
Transplantation, Autologous | 7 | 1.0 |
Erythropoietin/*genetics/metabolism | 5 | 71.0 |
Mice, Inbred Strains | 11 | 1.0 |
Antioxidants/*pharmacology | 2 | 1.0 |
Free Radical Scavengers/pharmacology | 2 | 3.0 |
Hydrogen Peroxide/pharmacology | 3 | 1.0 |
Kidney/*metabolism | 9 | 5.0 |
Vitamin A/pharmacology | 2 | 14.0 |
Erythropoietin/*analysis/blood | 2 | 100.0 |
Erythroid Progenitor Cells/cytology/metabolism | 2 | 22.0 |
Feedback | 6 | 3.0 |
Homeostasis | 5 | 1.0 |
Erythrocyte Volume/*physiology | 2 | 100.0 |
Spleen/*pathology/radionuclide imaging | 2 | 100.0 |
Bone Marrow Cells/*drug effects | 2 | 33.0 |
Bone Marrow/*drug effects/pathology | 2 | 20.0 |
Hematopoiesis/*drug effects | 8 | 8.0 |
Hematopoietic Stem Cells/drug effects | 4 | 6.0 |
Mice, Transgenic | 7 | 0.0 |
Macaca mulatta | 3 | 0.0 |
Reactive Oxygen Species/*metabolism | 2 | 1.0 |
Iron/metabolism | 14 | 11.0 |
Morbidity | 2 | 3.0 |
Polycythemia/*blood | 6 | 85.0 |
Postoperative Complications | 2 | 1.0 |
Sex Characteristics | 4 | 0.0 |
Carcinoma, Hepatocellular/metabolism | 5 | 5.0 |
Erythropoietin/antagonists & inhibitors/*biosynthesis | 2 | 100.0 |
Reactive Oxygen Species/metabolism | 3 | 0.0 |
Birth Weight | 6 | 3.0 |
Postpartum Period | 2 | 2.0 |
Sampling Studies | 2 | 1.0 |
Genotype | 2 | 0.0 |
Globins/genetics | 3 | 2.0 |
Reticulocytes/*physiology | 3 | 100.0 |
Receptors, Erythropoietin/*chemistry/*metabolism | 2 | 100.0 |
Recombinant Fusion Proteins/chemistry/metabolism | 2 | 1.0 |
src Homology Domains | 2 | 0.0 |
Erythroblastosis, Fetal/*blood/pathology | 2 | 100.0 |
Granulocyte Colony-Stimulating Factor/*blood | 3 | 50.0 |
Interleukin-3/*blood | 2 | 40.0 |
Polycythemia Vera/blood/*diagnosis | 5 | 100.0 |
Quality Control | 2 | 1.0 |
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use | 3 | 1.0 |
Enalapril/*therapeutic use | 4 | 8.0 |
*Phlebotomy | 3 | 100.0 |
Polycythemia/blood/*drug therapy | 2 | 100.0 |
*Hematopoietic Stem Cells | 2 | 4.0 |
Insulin/blood | 2 | 0.0 |
Medical Records | 2 | 2.0 |
Chromosomes, Human, Pair 7/*genetics | 2 | 1.0 |
Cloning, Molecular/methods | 4 | 2.0 |
Phylogeny | 2 | 0.0 |
Erythropoietin/blood/*genetics | 2 | 100.0 |
Polycythemia Vera/*blood/therapy | 3 | 75.0 |
Anemia, Hypochromic/*drug therapy/etiology | 2 | 100.0 |
Blood Chemical Analysis | 3 | 6.0 |
Risk Assessment | 3 | 0.0 |
Lymphatic Metastasis | 2 | 0.0 |
*Cardiac Surgical Procedures | 2 | 4.0 |
Protein Processing, Post-Translational | 4 | 0.0 |
Acrylic Resins | 2 | 8.0 |
Adsorption | 2 | 1.0 |
*Membranes, Artificial | 2 | 2.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
*Blood Donors | 8 | 7.0 |
Blood Transfusion, Autologous | 4 | 16.0 |
Algorithms | 4 | 1.0 |
Protein Structure, Secondary | 4 | 0.0 |
Nephrectomy | 8 | 9.0 |
Hematocrit/veterinary | 2 | 66.0 |
Anemia/blood/drug therapy | 2 | 100.0 |
Cytokines/*biosynthesis | 3 | 0.0 |
Drug Resistance | 7 | 1.0 |
Erythropoiesis/drug effects/physiology | 2 | 50.0 |
Interferon-gamma, Recombinant/pharmacology | 3 | 1.0 |
Interleukin-12/biosynthesis | 2 | 2.0 |
Interleukin-6/biosynthesis | 2 | 0.0 |
Lipopolysaccharides/pharmacology | 3 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 2 | 0.0 |
Anemia/*blood/diagnosis/*etiology | 2 | 100.0 |
Biopsy, Needle | 2 | 0.0 |
Anemia/*blood | 12 | 80.0 |
Vitamin B 12/*blood | 2 | 6.0 |
Cobalt/*pharmacology | 4 | 40.0 |
Hydrogen Peroxide/metabolism | 3 | 2.0 |
Nickel/*pharmacology | 2 | 25.0 |
Oxygen/*pharmacology | 3 | 15.0 |
Oxygen Consumption | 4 | 1.0 |
Signal Transduction/drug effects | 4 | 0.0 |
Spectrophotometry | 2 | 1.0 |
Metabolic Clearance Rate | 6 | 1.0 |
Recombinant Proteins/administration & dosage/therapeutic use | 10 | 26.0 |
Genes, Recessive | 2 | 0.0 |
Anemia/therapy | 2 | 50.0 |
Anemia, Refractory/*therapy | 2 | 66.0 |
Recombinant Proteins/*therapeutic use | 3 | 13.0 |
Carcinoma, Hepatocellular/drug therapy/metabolism | 2 | 50.0 |
Quinacrine/pharmacology | 2 | 13.0 |
Anemia/blood/*etiology/pathology | 2 | 100.0 |
Neoplasms/*complications/drug therapy/pathology | 2 | 100.0 |
Erythropoietin/*genetics/secretion | 3 | 100.0 |
Gene Transfer Techniques | 5 | 0.0 |
Asphyxia Neonatorum/blood/*diagnosis | 2 | 66.0 |
Fetal Distress/blood/*diagnosis | 2 | 100.0 |
Renin/*blood | 2 | 2.0 |
Anemia/etiology/therapy | 3 | 50.0 |
Carbohydrate Conformation | 2 | 1.0 |
Carbohydrate Sequence | 3 | 0.0 |
Exons | 4 | 0.0 |
Kidney Failure, Chronic/blood/complications/therapy | 4 | 30.0 |
Oligonucleotide Probes | 3 | 0.0 |
Oligosaccharides/chemistry | 2 | 7.0 |
Erythrocytes/chemistry | 2 | 4.0 |
Infant Food | 2 | 8.0 |
Infant, Newborn/*blood | 2 | 4.0 |
Protoporphyrins/blood | 2 | 9.0 |
Erythroid Progenitor Cells/cytology/*drug effects | 3 | 75.0 |
Anemia/*drug therapy | 12 | 85.0 |
Multiple Myeloma/*complications | 7 | 58.0 |
Bone Marrow/*pathology | 4 | 2.0 |
Cyclosporine/adverse effects | 2 | 12.0 |
Immunosuppressive Agents/adverse effects | 2 | 9.0 |
Polycythemia/*etiology/metabolism | 2 | 100.0 |
Antineoplastic Agents/adverse effects | 2 | 6.0 |
Anemia, Aplastic/*drug therapy | 2 | 50.0 |
Erythropoietin/blood/*therapeutic use | 10 | 100.0 |
Disease-Free Survival | 2 | 0.0 |
DNA-Binding Proteins/physiology | 2 | 0.0 |
Nuclear Proteins/physiology | 2 | 2.0 |
Organ Specificity | 5 | 0.0 |
Oxygen/*physiology | 3 | 14.0 |
*Allergens | 2 | 12.0 |
Eosinophils/drug effects/enzymology | 2 | 100.0 |
Carcinoma, Hepatocellular/pathology | 2 | 4.0 |
Liver Neoplasms/pathology | 2 | 4.0 |
Receptors, Erythropoietin/biosynthesis/genetics | 3 | 60.0 |
DNA, Viral/analysis | 2 | 0.0 |
Growth Substances/*pharmacology | 8 | 2.0 |
Hematopoietic Stem Cells/*drug effects | 5 | 7.0 |
Membrane Proteins/pharmacology | 2 | 4.0 |
Cell Hypoxia/genetics/physiology | 2 | 33.0 |
Cross-Linking Reagents | 4 | 1.0 |
Growth Substances/*physiology | 4 | 2.0 |
Hematopoietic Stem Cells/*drug effects/physiology | 2 | 15.0 |
Interleukin-6/*pharmacology | 4 | 1.0 |
Kidney Failure, Chronic/blood/therapy | 2 | 6.0 |
Bone Marrow Cells/physiology | 2 | 8.0 |
Clone Cells | 6 | 0.0 |
Neovascularization, Physiologic | 2 | 1.0 |
Receptors, Erythropoietin | 16 | 66.0 |
Erythropoietin/*physiology/*therapeutic use | 2 | 66.0 |
Ferritin/analysis | 2 | 11.0 |
Hemoglobins/*analysis | 10 | 19.0 |
Gerbillinae | 2 | 5.0 |
Infusions, Parenteral | 4 | 2.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Anemia, Iron-Deficiency/*blood | 2 | 25.0 |
Reticulocytes/*drug effects | 2 | 100.0 |
Blood Cell Count/drug effects | 2 | 9.0 |
Erythropoietin/administration & dosage/blood/*therapeutic use | 3 | 100.0 |
Antineoplastic Combined Chemotherapy Protocols/*adverse effects | 2 | 4.0 |
Erythropoietin/*blood/*therapeutic use | 5 | 100.0 |
Peroxidases/metabolism | 5 | 20.0 |
Erythroid Progenitor Cells/drug effects | 4 | 28.0 |
Reticulocytes/drug effects | 3 | 60.0 |
Potassium/blood | 3 | 3.0 |
Erythrocyte Count/drug effects | 9 | 90.0 |
Hemoglobins/drug effects/metabolism | 5 | 55.0 |
*Mutation | 4 | 0.0 |
Polycythemia/*genetics | 3 | 27.0 |
Recombinant Proteins/pharmacology/therapeutic use | 2 | 5.0 |
Anemia/*therapy | 7 | 87.0 |
Fetal Blood/*metabolism | 5 | 10.0 |
Uremia/complications | 2 | 40.0 |
Longitudinal Studies | 4 | 0.0 |
*Sports | 2 | 6.0 |
Anemia/blood/etiology/*therapy | 9 | 100.0 |
Neutrophils/*enzymology | 3 | 2.0 |
Point Mutation | 3 | 0.0 |
Cell Survival | 3 | 0.0 |
Graft vs Host Disease/prevention & control | 2 | 3.0 |
Hematopoietic Cell Growth Factors/*pharmacology | 9 | 19.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Kidney Failure, Chronic/blood/*complications/therapy | 3 | 30.0 |
Parathyroid Hormone/blood | 2 | 1.0 |
Biological Availability | 6 | 2.0 |
Isoelectric Focusing | 4 | 0.0 |
Mice, Inbred CBA | 4 | 1.0 |
Reticulocytes/metabolism | 3 | 4.0 |
Peroxidases/*secretion | 2 | 100.0 |
Blood Transfusion, Autologous/*methods | 3 | 60.0 |
Erythropoietin/*administration & dosage/adverse effects | 2 | 100.0 |
Recombinant Proteins/administration & dosage/adverse effects | 2 | 18.0 |
Anemia/*blood/therapy | 2 | 100.0 |
Erythropoietin/adverse effects/*therapeutic use | 11 | 100.0 |
Granulocyte Colony-Stimulating Factor/adverse effects/*therapeutic use | 2 | 50.0 |
Tissue Distribution | 8 | 0.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
*Quality of Life | 4 | 4.0 |
Models, Animal | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
Anemia/blood/drug therapy/etiology | 2 | 100.0 |
Polymers | 2 | 1.0 |
Sulfones | 2 | 10.0 |
DNA, Recombinant | 2 | 1.0 |
Gene Expression Regulation/*genetics | 2 | 1.0 |
Adenoviridae/*genetics | 2 | 0.0 |
Macaca fascicularis | 3 | 1.0 |
Virus Replication | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Erythropoietin/administration & dosage | 4 | 57.0 |
*Hematopoiesis/drug effects | 4 | 25.0 |
Myelodysplastic Syndromes/blood/*drug therapy | 2 | 50.0 |
Hydrogen Peroxide/*pharmacology | 2 | 3.0 |
Peptide Mapping | 2 | 0.0 |
Anemia/*etiology/*therapy | 2 | 66.0 |
Antibodies, Monoclonal/*pharmacology | 2 | 1.0 |
Arthritis, Rheumatoid/*complications/immunology | 2 | 40.0 |
C-Reactive Protein/metabolism | 2 | 0.0 |
*Diabetes Complications | 3 | 5.0 |
Kidney Function Tests | 6 | 5.0 |
Interleukin-2/blood | 2 | 2.0 |
Polycythemia | 2 | 66.0 |
Erythroid Progenitor Cells/*cytology/metabolism | 3 | 75.0 |
Bone Marrow Cells | 23 | 5.0 |
Erythropoietin/blood/pharmacology | 5 | 100.0 |
Polycythemia Vera/*pathology | 2 | 66.0 |
Hematopoietic Stem Cells/pathology | 3 | 7.0 |
Kidney Transplantation/*adverse effects/physiology | 2 | 100.0 |
Erythropoietin/metabolism/pharmacology | 3 | 37.0 |
Recombinant Proteins/metabolism/pharmacology | 2 | 1.0 |
Ferrous Compounds/administration & dosage | 2 | 100.0 |
Blood Urea Nitrogen | 2 | 3.0 |
Iron/blood/*deficiency | 2 | 40.0 |
Ferritin/metabolism | 6 | 20.0 |
Erythropoietin/*biosynthesis/*genetics | 2 | 100.0 |
Recombinant Fusion Proteins/biosynthesis | 3 | 0.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Arteriovenous Shunt, Surgical/*adverse effects | 2 | 40.0 |
Serum Albumin/metabolism | 3 | 1.0 |
Cytokines/pharmacology | 8 | 2.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Trans-Activators/*physiology | 2 | 0.0 |
Tyrosine/metabolism | 3 | 0.0 |
Kidney/*drug effects/*metabolism | 3 | 60.0 |
Single-Blind Method | 5 | 2.0 |
Erythroblasts/drug effects/*metabolism | 3 | 100.0 |
Proto-Oncogene Proteins/*metabolism | 3 | 0.0 |
Signal Transduction/*drug effects | 4 | 1.0 |
Blood Viscosity | 2 | 5.0 |
Erythropoietin/adverse effects/blood/*therapeutic use | 5 | 100.0 |
Kidney/*physiopathology | 2 | 3.0 |
Anemia/drug therapy/*etiology | 2 | 100.0 |
Cytokines/physiology | 3 | 1.0 |
Erythropoietin/physiology/therapeutic use | 2 | 100.0 |
Interleukin-6/physiology | 2 | 3.0 |
Tumor Necrosis Factor-alpha/physiology | 2 | 1.0 |
*Heterozygote | 2 | 0.0 |
3T3 Cells | 3 | 0.0 |
Lymphokines/pharmacology | 2 | 1.0 |
Eosinophils | 2 | 5.0 |
Anemia, Aplastic/blood/*therapy | 2 | 40.0 |
Receptors, Transferrin/analysis | 6 | 16.0 |
Recombinant Proteins/adverse effects/therapeutic use | 6 | 19.0 |
Erythropoietin/metabolism/*physiology | 2 | 100.0 |
Brain/blood supply | 2 | 5.0 |
Chromatography, Gel | 5 | 0.0 |
Swine | 4 | 0.0 |
*Neoplasm Proteins | 4 | 0.0 |
*Receptors, Cytokine | 3 | 2.0 |
Trans-Activators/*metabolism | 4 | 0.0 |
Anemia/physiopathology | 2 | 100.0 |
Dialysis Solutions | 4 | 22.0 |
Membranes, Artificial | 2 | 2.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Glycoproteins/analysis | 2 | 3.0 |
Peroxidases/analysis | 2 | 22.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/physiology | 2 | 7.0 |
Interleukin-3/physiology | 2 | 6.0 |
Umbilical Veins/cytology | 2 | 0.0 |
Blood Pressure/physiology | 5 | 2.0 |
Administration, Inhalation | 2 | 1.0 |
Microscopy, Electron | 7 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Phosphoproteins/chemistry/metabolism | 2 | 8.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Perfusion | 2 | 0.0 |
Deferoxamine/*pharmacology | 2 | 25.0 |
Blood-Brain Barrier | 2 | 3.0 |
Oxygen/pharmacology | 2 | 5.0 |
Receptor, Insulin/metabolism | 2 | 2.0 |
Cell Transplantation | 4 | 4.0 |
Retroviridae/*genetics | 2 | 1.0 |
Hemorrhage/blood | 3 | 42.0 |
Theophylline/therapeutic use | 2 | 50.0 |
*Blood Transfusion, Autologous | 7 | 28.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 6 | 3.0 |
Megakaryocytes/*cytology | 8 | 15.0 |
Neutralization Tests | 2 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Recombinant Proteins/administration & dosage | 7 | 8.0 |
Cattle | 3 | 0.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*metabolism | 2 | 0.0 |
Polycythemia/etiology | 5 | 100.0 |
Platelet Aggregation/*drug effects | 2 | 1.0 |
Theophylline/pharmacology | 2 | 5.0 |
Erythropoietin/*pharmacokinetics | 2 | 100.0 |
Recombinant Proteins/pharmacokinetics | 4 | 22.0 |
Sheep | 3 | 0.0 |
Neuroprotective Agents/*pharmacology | 2 | 2.0 |
Cost Control | 2 | 66.0 |
Renal Dialysis/adverse effects | 5 | 17.0 |
Hypertension/*physiopathology | 2 | 3.0 |
Renin-Angiotensin System/physiology | 3 | 6.0 |
Sodium/blood | 2 | 1.0 |
Reticulocytes/*pathology | 2 | 50.0 |
Leukemia, Myelocytic, Acute/*genetics/pathology | 2 | 6.0 |
Stem Cells/pathology | 2 | 10.0 |
Antibodies, Monoclonal/pharmacology | 4 | 0.0 |
Liver Neoplasms/metabolism | 4 | 5.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*blood | 2 | 25.0 |
Apgar Score | 3 | 13.0 |
Iron/deficiency | 4 | 30.0 |
Gene Expression/*drug effects | 2 | 0.0 |
Hydrogen Peroxide/metabolism/*pharmacology | 2 | 50.0 |
Vitamin K/pharmacology | 2 | 10.0 |
Arginine | 2 | 2.0 |
Erythroid Progenitor Cells/*drug effects/pathology | 4 | 100.0 |
*Disease Models, Animal | 3 | 0.0 |
Mice, Inbred NZB | 2 | 6.0 |
Peroxidase/*deficiency | 2 | 13.0 |
*Antigens, CD | 2 | 0.0 |
Antigens, Differentiation/analysis | 2 | 0.0 |
*Bone Marrow Cells | 12 | 4.0 |
Cell Cycle | 3 | 0.0 |
*Erythropoiesis/drug effects | 5 | 62.0 |
Spleen/cytology | 4 | 2.0 |
Blood Volume/physiology | 2 | 18.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Hydrogen-Ion Concentration | 9 | 0.0 |
Aging/blood | 2 | 3.0 |
Blood Transfusion, Intrauterine/*methods | 2 | 100.0 |
Erythropoietin/blood/deficiency/*therapeutic use | 2 | 100.0 |
Protein Biosynthesis | 2 | 0.0 |
Anemia, Aplastic/*blood | 2 | 16.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Tryptophan | 2 | 7.0 |
Tyrosine | 2 | 1.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
Hemeproteins/*physiology | 2 | 50.0 |
Iron/pharmacology | 2 | 11.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
Leukemia, Erythroblastic, Acute/metabolism | 2 | 11.0 |
RNA/analysis | 2 | 0.0 |
Mammals | 2 | 0.0 |
Arthritis, Juvenile Rheumatoid/blood/*complications/physiopathology | 2 | 100.0 |
Life Tables | 2 | 1.0 |
RNA, Messenger/genetics | 9 | 0.0 |
*Chromosomes, Human, Pair 7 | 3 | 1.0 |
Hospitalization | 2 | 1.0 |
Proportional Hazards Models | 4 | 0.0 |
Placenta/*metabolism | 2 | 1.0 |
Erythropoietin/*blood/therapeutic use | 8 | 100.0 |
Peritoneal Dialysis, Continuous Ambulatory/*adverse effects | 3 | 7.0 |
Platelet Count/drug effects | 2 | 5.0 |
Safety | 3 | 2.0 |
Whole-Body Irradiation/adverse effects | 2 | 22.0 |
Protein-Tyrosine Kinase/genetics/metabolism | 2 | 2.0 |
Erythropoietin/administration & dosage/*pharmacokinetics | 3 | 100.0 |
Iron/therapeutic use | 5 | 50.0 |
Prevalence | 2 | 0.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
Catalase/pharmacology | 4 | 10.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
RNA, Neoplasm/metabolism | 2 | 2.0 |
Polycythemia/*drug therapy | 2 | 100.0 |
Cell Death | 2 | 0.0 |
Liver/drug effects/embryology | 2 | 100.0 |
Recombinant Proteins/*pharmacology | 3 | 3.0 |
Hemodynamic Processes/drug effects | 2 | 1.0 |
Enalapril/pharmacology | 2 | 7.0 |
Anoxia/*blood | 5 | 33.0 |
Retroviridae/genetics | 6 | 1.0 |
Bromides/pharmacology | 2 | 50.0 |
Iodides/pharmacology | 3 | 37.0 |
Tetradecanoylphorbol Acetate/pharmacology | 8 | 0.0 |
Hypertension/chemically induced/*physiopathology | 2 | 66.0 |
Kidney Transplantation/adverse effects/*physiology | 2 | 50.0 |
Erythropoietin/*administration & dosage/blood | 3 | 100.0 |
Receptors, Transferrin/*metabolism | 3 | 13.0 |
Pregnancy Complications | 2 | 7.0 |
DNA Primers | 6 | 0.0 |
Anaerobiosis | 2 | 8.0 |
Sequence Homology, Nucleic Acid | 9 | 0.0 |
Neoplasms/blood/*complications | 2 | 33.0 |
RNA, Messenger/analysis/biosynthesis | 4 | 1.0 |
Anemia, Iron-Deficiency/blood | 5 | 71.0 |
Hemolysis | 3 | 0.0 |
Enalapril/adverse effects/*therapeutic use | 2 | 33.0 |
*Erythroid Progenitor Cells | 2 | 66.0 |
Graft Survival | 3 | 0.0 |
Reticulocytes | 7 | 22.0 |
Oxygen/*blood/metabolism | 2 | 66.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
*Prenatal Diagnosis | 2 | 0.0 |
Biological Assay/*methods | 4 | 9.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 2 | 1.0 |
Bone Marrow/*metabolism | 3 | 6.0 |
Hematopoietic Stem Cells/cytology | 7 | 7.0 |
Erythropoietin/metabolism/*therapeutic use | 3 | 100.0 |
Osmotic Fragility | 2 | 16.0 |
Erythropoietin/*secretion | 2 | 100.0 |
Circadian Rhythm/physiology | 2 | 3.0 |
Megakaryocytes/cytology/*drug effects | 2 | 20.0 |
Forskolin/pharmacology | 2 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Uremia/*complications | 2 | 20.0 |
Cyclic AMP/metabolism | 3 | 0.0 |
Erythropoietin, Recombinant/*analysis | 2 | 100.0 |
Bloodletting | 5 | 41.0 |
Recombinant Proteins/*biosynthesis | 2 | 5.0 |
Thyrotropin/blood | 2 | 0.0 |
Infant, Premature, Diseases/*drug therapy | 2 | 50.0 |
Genes, Dominant | 2 | 0.0 |
Anemia/blood/chemically induced/*drug therapy | 2 | 100.0 |
*Sex Characteristics | 2 | 1.0 |
Anemia, Hemolytic/blood | 2 | 25.0 |
Arthritis, Rheumatoid/*blood | 3 | 6.0 |
Receptors, Transferrin/*analysis | 2 | 18.0 |
Sports Medicine | 2 | 33.0 |
Leukemia, Megakaryocytic, Acute | 2 | 20.0 |
Megakaryocytes/*metabolism | 2 | 6.0 |
Receptors, Immunologic/metabolism | 2 | 1.0 |
Down-Regulation | 4 | 0.0 |
Friend murine leukemia virus | 2 | 28.0 |
Rats, Inbred Strains | 14 | 1.0 |
Bucladesine/pharmacology | 2 | 1.0 |
Cytochalasin B/pharmacology | 4 | 4.0 |
Neurotoxins/analysis | 2 | 66.0 |
Autoradiography | 2 | 0.0 |
Kidney Failure, Chronic/complications/*therapy | 2 | 25.0 |
Syndrome | 2 | 0.0 |
Anemia/*blood/pathology | 2 | 66.0 |
Reticulocytes/*cytology | 2 | 33.0 |
Erythropoietin/*adverse effects/therapeutic use | 2 | 66.0 |
Thrombosis/etiology | 3 | 4.0 |
Random Allocation | 2 | 0.0 |
Energy Metabolism | 2 | 1.0 |
Antigens, CD/*analysis | 3 | 0.0 |
Cell Separation/methods | 3 | 1.0 |
Culture Techniques/methods | 4 | 7.0 |
Hematopoietic Stem Cells/*cytology/drug effects/immunology | 2 | 11.0 |
Stem Cell Factor | 9 | 9.0 |
Hematopoietic Cell Growth Factors/*therapeutic use | 3 | 50.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Lymphokines/*pharmacology | 2 | 0.0 |
Anemia, Neonatal/*physiopathology/*therapy | 2 | 100.0 |
Body Weight | 3 | 0.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Oligodeoxyribonucleotides | 3 | 0.0 |
Endoplasmic Reticulum/*metabolism | 2 | 1.0 |
Kidney | 4 | 1.0 |
*Protein Folding | 2 | 1.0 |
Erythropoietin/pharmacology/*therapeutic use | 2 | 50.0 |
Erythropoietin/*biosynthesis/therapeutic use | 2 | 100.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*administration & dosage | 2 | 11.0 |
Erythropoietin/metabolism/*pharmacology | 2 | 66.0 |
Immunosorbent Techniques | 2 | 0.0 |
Leukemia, Erythroblastic, Acute | 4 | 4.0 |
Kidney/physiology | 4 | 7.0 |
Renin-Angiotensin System/*physiology | 2 | 3.0 |
Erythropoietin/*biosynthesis/genetics/*physiology | 2 | 100.0 |
Fetus/physiology | 2 | 4.0 |
Polycythemia/*blood/etiology | 2 | 66.0 |
Parathyroidectomy | 2 | 8.0 |
Genes, Structural | 3 | 0.0 |
Megakaryocytes/cytology | 3 | 12.0 |
Interleukin-1/pharmacology | 7 | 1.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 4 | 1.0 |
Fluorescence | 3 | 1.0 |
Erythropoietin/*biosynthesis/blood/genetics | 2 | 100.0 |
Amitrole/pharmacology | 4 | 40.0 |
Multicenter Studies | 2 | 1.0 |
Anemia, Aplastic/*blood/therapy | 2 | 66.0 |
Immunosuppression | 3 | 1.0 |
DNA | 4 | 0.0 |
Up-Regulation | 3 | 0.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 3 | 1.0 |
Recombinant Proteins/administration & dosage/pharmacokinetics | 2 | 20.0 |
Uremia/blood/*metabolism | 2 | 100.0 |
*Surgical Procedures, Operative | 2 | 6.0 |
Hemoglobins/biosynthesis | 3 | 18.0 |
Proto-Oncogene Proteins c-myb | 2 | 3.0 |
Cytokines/*physiology/therapeutic use | 2 | 33.0 |
Peroxidases/*genetics | 2 | 18.0 |
Physical Endurance/*physiology | 2 | 4.0 |
alpha-Fetoproteins/analysis | 2 | 0.0 |
Lung Diseases, Obstructive/*blood/therapy | 2 | 100.0 |
*Bloodletting | 3 | 75.0 |
Blood Component Transfusion | 3 | 18.0 |
*Protein Structure, Tertiary | 2 | 1.0 |
Erythropoietin | 2 | 33.0 |
Cisplatin/adverse effects | 2 | 40.0 |
Cell Division/*drug effects | 4 | 1.0 |
Spleen Focus-Forming Viruses/*genetics | 2 | 66.0 |
Erythropoietin/*administration & dosage/blood/therapeutic use | 2 | 100.0 |
Cardiovascular Diseases/epidemiology | 2 | 7.0 |
Incidence | 2 | 0.0 |
Treatment Failure | 2 | 0.0 |
Gene Expression/genetics | 2 | 0.0 |
Colony-Stimulating Factors/*pharmacology | 4 | 8.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/physiology | 2 | 1.0 |
DNA/genetics | 7 | 0.0 |
Oxygen Consumption/physiology | 2 | 2.0 |
N-Formylmethionine Leucyl-Phenylalanine/*pharmacology | 2 | 4.0 |
Uremia/therapy | 3 | 37.0 |
Recombinant Proteins/pharmacokinetics/therapeutic use | 3 | 30.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
DNA, Recombinant/genetics | 2 | 3.0 |
Recombinant Fusion Proteins/biosynthesis/genetics | 2 | 2.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Leukocyte Count/drug effects | 3 | 2.0 |
Myelodysplastic Syndromes/*blood/genetics/pathology | 2 | 66.0 |
Erythropoietin/biosynthesis/*therapeutic use | 2 | 100.0 |
Blood Platelets/physiology | 2 | 3.0 |
Erythrocytes/*drug effects | 2 | 9.0 |
Carcinoma, Hepatocellular/*metabolism/pathology | 2 | 3.0 |
Liver Neoplasms/*metabolism/pathology | 3 | 4.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Creatine/blood | 2 | 16.0 |
Kidney Failure, Chronic/*metabolism/therapy | 2 | 14.0 |
Peritoneal Cavity/cytology | 2 | 4.0 |
Reticulocytes/pathology | 2 | 25.0 |
Absorption | 2 | 1.0 |
Activins | 2 | 2.0 |
Granulocytes/cytology | 8 | 16.0 |
Macrophages/cytology | 6 | 8.0 |
*Genes, Structural | 3 | 0.0 |
Hematologic Diseases/blood | 2 | 28.0 |
Kidney Failure, Chronic/blood | 5 | 20.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay/methods | 4 | 1.0 |
Hematologic Diseases/*blood | 2 | 20.0 |
Anemia/diagnosis | 2 | 66.0 |
T-Lymphocytes | 2 | 0.0 |
Anemia, Hypochromic/blood | 7 | 58.0 |
Brain Injuries/prevention & control | 2 | 100.0 |
Cerebrovascular Accident/drug therapy | 2 | 50.0 |
Peru | 2 | 4.0 |
Kidney Failure, Acute/*blood/complications | 2 | 100.0 |
Anemia/blood/*etiology/therapy | 2 | 100.0 |
*Blood Viscosity | 2 | 16.0 |
Multiple Myeloma/*blood | 2 | 8.0 |
Erythropoietin/analysis/*biosynthesis | 4 | 100.0 |
Anemia/blood/*therapy | 3 | 75.0 |
Anemia/chemically induced/*prevention & control | 2 | 100.0 |
Cell Differentiation/*drug effects | 3 | 1.0 |
Blood Pressure/*physiology | 2 | 2.0 |
Blood | 4 | 2.0 |
Acquired Immunodeficiency Syndrome/blood | 2 | 11.0 |
Kidney/embryology/*metabolism | 2 | 13.0 |
Neoplasms/*blood/complications | 2 | 18.0 |
Anoxia/*blood/complications | 2 | 66.0 |
Renin-Angiotensin System/drug effects | 2 | 3.0 |
Red-Cell Aplasia, Pure/etiology | 2 | 100.0 |
Biological Assay/methods | 5 | 13.0 |
Anemia/blood/pathology | 2 | 100.0 |
Receptors, Cell Surface/metabolism | 3 | 0.0 |
Erythropoietin/administration & dosage/blood/*pharmacokinetics | 2 | 100.0 |
Kidney Failure, Chronic/*blood/complications/therapy | 3 | 27.0 |
*Reagent Kits, Diagnostic | 2 | 3.0 |
*Cloning, Molecular | 4 | 1.0 |
Centrifugation, Density Gradient | 2 | 0.0 |
Colony-Forming Units Assay/methods | 2 | 33.0 |
Erythropoietin/analysis/*blood/pharmacology | 2 | 100.0 |
Liver/drug effects/physiology | 2 | 33.0 |
Polycythemia Vera/blood | 6 | 46.0 |
Alkaloids/pharmacology | 2 | 1.0 |
Staurosporine | 2 | 2.0 |
*Bone Marrow Transplantation/adverse effects | 2 | 7.0 |
Cadaver | 2 | 0.0 |
Immunization | 2 | 0.0 |
Antigens, Surface/analysis | 3 | 0.0 |
Growth Substances/immunology | 2 | 20.0 |
Granulocytes/physiology | 3 | 15.0 |
2,3-Diphosphoglycerate | 2 | 14.0 |
Erythropoietin/*administration & dosage/genetics | 3 | 100.0 |
Recombination, Genetic | 2 | 0.0 |
Urea/blood | 2 | 6.0 |
Epitopes/immunology | 2 | 0.0 |
Transforming Growth Factor beta/pharmacology | 3 | 0.0 |
Renal Dialysis/*methods | 5 | 17.0 |
Antibodies/*analysis | 2 | 1.0 |
Interferon-gamma, Recombinant/*pharmacology | 2 | 1.0 |
Gene Expression Regulation/genetics | 2 | 1.0 |
Recombinant Proteins/analysis | 2 | 4.0 |
Anemia/blood/etiology/therapy | 2 | 66.0 |
Kidney Failure, Chronic/*complications/physiopathology | 2 | 33.0 |
Kidney Diseases/metabolism | 2 | 7.0 |
Leukemia, Erythroblastic, Acute/*pathology | 3 | 21.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Kidney Failure, Chronic/*blood/*therapy | 2 | 15.0 |
Erythropoietin/*deficiency/pharmacokinetics/therapeutic use | 2 | 100.0 |
Erythropoietin/*deficiency | 2 | 100.0 |
Histocytochemistry | 2 | 0.0 |
Nutrition Disorders/complications | 2 | 18.0 |
Erythrocyte Volume/physiology | 2 | 100.0 |
Biological Markers/*blood | 3 | 1.0 |
Thalassemia/*blood/therapy | 2 | 100.0 |
Ultrafiltration | 2 | 3.0 |
Receptors, Cell Surface/genetics/*metabolism | 2 | 1.0 |
Iodine Radioisotopes/diagnostic use | 3 | 0.0 |
Tissue Inhibitor of Metalloproteinases | 5 | 7.0 |
Phenylhydrazines | 3 | 60.0 |
Eosinophils/enzymology/*physiology | 2 | 100.0 |
Superoxides/metabolism | 2 | 0.0 |
Cyclosporins/therapeutic use | 2 | 5.0 |
Receptors, Cell Surface/*genetics | 2 | 0.0 |
Polycythemia/diagnosis | 2 | 100.0 |
Recombinant Proteins/diagnostic use | 2 | 9.0 |
Granulocyte Colony-Stimulating Factor | 2 | 10.0 |
Gene Amplification | 4 | 0.0 |
Chlorides/pharmacology | 2 | 5.0 |
Neuroprotective Agents/therapeutic use | 2 | 20.0 |
Erythroblasts/pathology | 2 | 28.0 |
Colony-Stimulating Factors/pharmacology | 6 | 13.0 |
Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 6.0 |
Hematopoietic Stem Cells/*physiology | 4 | 3.0 |
Growth Substances/pharmacology | 2 | 1.0 |
Chromatography | 2 | 1.0 |
Hydroxyapatites | 2 | 14.0 |
Inflammation/*blood | 2 | 4.0 |
Hindlimb | 2 | 8.0 |
Anemia, Aplastic/blood | 3 | 33.0 |
*Megakaryocytes | 2 | 16.0 |
DNA/analysis | 2 | 0.0 |
Haplorhini | 2 | 0.0 |
Homozygote | 3 | 0.0 |
Electrophoresis, Capillary/*methods | 2 | 6.0 |
Purpura, Thrombocytopenic/*urine | 2 | 100.0 |
Erythropoietin/*blood/pharmacology | 2 | 100.0 |
Bone Marrow/*drug effects/metabolism | 2 | 50.0 |
Heme/metabolism | 3 | 11.0 |
Ligases/*genetics | 2 | 1.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
